Expression levels and clinical significance of three kinds of miRNAs in patients with MDS
-
摘要: 目的:探究骨髓增生异常综合征(MDS)患者血浆mi-21、miR-155、miR-210表达水平及其临床意义。方法:选择2016年6月—2020年6月收治83例MDS患者作为研究组,同一时间体检40例健康者作为对照组,均测定血浆miR-21、miR-155、miR-210表达水平,分析2组3种miRNA差异及临床意义。研究组按照WTO分型、国际预后积分系统(IPSS)评分进行分组,比较不同WTO分型、IPSS评分患者血浆miRNA水平,分析3种血浆miRNA表达水平与WTO分型、IPSS评分之间相关性。结果:研究组患者血浆miR-21、miR-155、miR-210表达水平均显著高于对照组(P<0.05);ROC曲线显示,血浆miR-21、miR-155、miR-210用于诊断MDS患者病情AUC值分别为0.989、0.887、0.950;难治性贫血伴原始细胞增多型患者血浆miR-21、miR-155、miR-210表达水平显著高于难治性贫血型与难治性血细胞减少伴多系发育异常型(P<0.05);血浆miR-21、miR-155、miR-210表达水平与WTO分型呈正相关(r=0.406、519、0.487;P<0.05);高危组患者血浆miR-21、miR-155、miR-210表达水平显著高于低危组与中危组(P<0.05),中危组患者血浆3种miRNA表达水平显著高于低危组(P<0.05);血浆miR-21、miR-155、miR-210表达水平与IPSS评分呈正相关(r=0.612、0.814、0.553;P<0.05)。结论:血浆miR-21、miR-155以及miR-210表达水平可用于预测MDS发生,对于评估患者病情进展意义重大,可以为患者及时治疗提供临床依据。Abstract: Objective: To explore the expression levels and clinical significance of plasma miR-21, miR-155 and miR-210 in patients with myelodysplastic syndrome(MDS).Methods: A total of 83 MDS patients(study group) admitted to the hospital from June 2016 to June 2020 and 40 healthy individuals(control group) receiving physical examination during the same period were enrolled as the research objects. The expression levels of plasma miR-21, miR-155 and miR-210 were measured. Differences in the three kinds of miRNA in the two groups and their clinical significance were analyzed. Patients in the study group were grouped according to WTO classification and the International Prognostic Scoring System(IPSS) score. The plasma miRNA levels of patients with different WTO classification and different IPSS scores were compared. Meanwhile, the relationship of expression levels of the three kinds of plasma miRNAs with WTO classification and IPSS score was analyzed.Results: The expression levels of plasma miR-21, miR-155 and miR-210 in study group were significantly higher than those in control group(P<0.05). ROC curves showed that AUC values of plasma miR-21, miR-155 and miR-210 for diagnosis of MDS were 0.989, 0.887 and 0.950, respectively. The expression levels of miR-21, miR-155 and miR-210 in patients with refractory anemia with excess of blasts were significantly higher than those with refractory anemia and refractory cytopenia with multilineage dysplasia(P<0.05). The expression levels of plasma miR-21, miR-155 and miR-210 were positively correlated with WTO classification(r=0.406, 519, 0.487. P<0.05). The expression levels of plasma miR-21, miR-155 and miR-210 in high-risk group were significantly higher than those in low-risk group and moderate-risk group(P<0.05). The expression levels of their miRNA in moderate-risk group were significantly higher than those in low-risk group(P<0.05). The expression levels of plasma miR-21, miR-155 and miR-210 were positively correlated with IPSS score(r=0.612, 0.814, 0.553. P<0.05).Conclusion: The expression levels of plasma miR-21, miR-155 and miR-210 can be applied to predict the occurrence of MDS, which may be of great significance for assessing the progression of patients' conditions, and can provide clinical evidence for timely treatment.
-
Key words:
- myelodysplastic syndrome /
- miR-21 /
- miR-155 /
- miR-210
-
-
[1] 于修文,杨慧健.原始细胞不增多骨髓增生异常综合征骨髓细胞发育异常特征分析[J].临床血液学杂志,2019,32(6):418-422.
[2] 王方方,杭筱,施青青,等.Tim3在再生障碍性贫血和骨髓增生异常综合征鉴别诊断中的意义[J].南京医科大学学报(自然科学版),2020,40(3):403-408.
[3] 邵明,汤平,吕先萍,等.ABO血型基因启动子甲基化水平在成人白血病和骨髓增生异常综合征中的临床意义和预后分析[J].中华内科杂志,2018,57(11):816-823.
[4] 崔佳奇,魏春梅,邓琳丽,等.miR-143通过抑制AF9调控SKM-1细胞增殖和凋亡[J].第三军医大学学报,2018,40(20):1826-1832.
[5] 张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:103-116.
[6] 岳兰竹.骨髓增生异常综合征诊断研究进展—维也纳诊断标准及2008 WHO诊断标准解读[J].国际输血及血液学杂志,2010,33(3):195-198.
[7] Greenberg PL,Heinz L,Schanz L,et al.Revised international prognostic scoring system for myelodysplastic syndromes.[J].Blood,2012,120(12):2454-65.
[8] Muench DE,Ferchen K,Velu CS,et al.SKI controls MDS-associated chronic TGF-β signaling,aberrant splicing,and stem cell fitness[J].Blood,2018,132(21):24-34.
[9] Bayraktar R,Van Roosbroeck K.miR-155 in cancer drug resistance and as target for miRNA-based therapeutics[J].Cancer Metastasis Rev,2018,37(1):33-44.
[10] Wang S,Xu Z,Wang L.Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression:mechanism and therapeutic targets from the aspect of microRNAs[J].Oncotarget,2017,8(37):62154-62166.
[11] Li G,Song Y,Li G,et al.Downregulation of microRNA21 expression inhibits proliferation,and induces G1 arrest and apoptosis via the PTEN/AKT pathway in SKM1 cells[J].Mol Med Rep,2018,18(3):2771-2779.
[12] Cao M,Shikama Y,Kimura H,et al.Mechanisms of Impaired Neutrophil Migration by MicroRNAs in Myelodysplastic Syndromes[J].J Immunol,2017,198(5):1887-1899.
[13] 胡应霞,张海蓉,石围,等.血浆miR-155,miR-196a,miR-21和miR-210对胰腺癌的早期诊断价值)[J].肿瘤,2016,35(10):1135-1143.
[14] 冀小波,何玮,朱文伟,等.骨髓增生异常综合征西医危险度转化与中医脏腑传变的相关性研究[J].辽宁中医杂志,2017,479(4):673-676.
[15] Choi Y,Hur EH,Moon JH,et al.Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome[J].Korean J Intern Med,2019,34(2):390-400.
[16] Hassan NM,Refaat LA,Ismail GN,et al.Diagnostic,prognostic and predictive values of miR-100 and miR-210 in pediatric acute lymphoblastic Leukemia[J].Hematology,2020,25(1):405-413.
[17] Huang HH,Chen FY,Chou WC,et al.Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome[J].BMC Cancer,2019,19(1):617.
-
计量
- 文章访问数: 353
- PDF下载数: 160
- 施引文献: 0
下载: